MSMB and acute lymphoblastic leukemia: Mutations in PRPS increase the metabolic vulnerability of the patients with acute lymphoblastic leukemia (ALL), thereby reducing relapse and progression (Srivastava et al., 2021; Song et al., 2023), which is also seen in colorectal and hepatocellular carcinomas (Li et al., 2016; Jing et al., 2019).